PT - JOURNAL ARTICLE AU - Fernandez-Cassi, Xavier AU - Scheidegger, Andreas AU - Bänziger, Carola AU - Cariti, Federica AU - Corzon, Alex Tuñas AU - Ganesanandamoorthy, Pravin AU - Lemaitre, Joseph C. AU - Ort, Christoph AU - Julian, Timothy R. AU - Kohn, Tamar TI - Wastewater monitoring outperforms case numbers as a tool to track COVID-19 incidence dynamics when test positivity rates are high AID - 10.1101/2021.03.25.21254344 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.25.21254344 4099 - http://medrxiv.org/content/early/2021/03/26/2021.03.25.21254344.short 4100 - http://medrxiv.org/content/early/2021/03/26/2021.03.25.21254344.full AB - Wastewater-based epidemiology (WBE) has been shown to coincide with, or anticipate, confirmed COVID-19 case numbers. During periods with high test positivity rates, however, case numbers may be underreported, whereas wastewater does not suffer from this limitation. Here we investigated how the dynamics of new COVID-19 infections estimated based on wastewater monitoring or confirmed cases compare to true COVID-19 incidence dynamics. We focused on the first pandemic wave in Switzerland (February to April, 2020), when test positivity ranged up to 26%. SARS-CoV-2 RNA loads were determined 2-4 times per week in three Swiss wastewater treatment plants (Lugano, Lausanne and Zurich). Wastewater and case data were combined with a shedding load distribution and an infection-to-case confirmation delay distribution, respectively, to estimate incidence dynamics. Finally, the estimates were compared to reference incidence dynamics determined by a validated compartmental model. Incidence dynamics estimated based on wastewater data were found to better track the timing and shape of the reference infection peak compared to estimates based on confirmed cases. In contrast, case confirmations provided a better estimate of the subsequent decline in infections. Under a regime of high-test positivity rates, WBE thus provides critical information that is complementary to clinical data to monitor the pandemic trajectory.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSwiss National Science Foundation (project 31CA30_196538) Eawag discretionary funds EPFL COVID19 grant Horizon 2020 research and innovation programme under the Marie Skłodowska Curie Grant Agreement No. 754462.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available on an institutional repository upon acceptance of the manuscript.